[Real data o viral hepatitis C therapy in the Czech Republic]

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C remains a significant global health concern.
• Interferon-free therapies have revolutionized hepatitis C treatment.
• Real-world data on novel treatment regimens are crucial for clinical practice.

Purpose of the Study:

• To evaluate the efficacy of an interferon-free regimen for chronic hepatitis C in the Czech Republic.
• To assess the sustained virological response (SVR12) in a diverse patient population.
• To report the first real-world data on this specific combination therapy.

Main Methods:

• A cohort of 109 chronic hepatitis C patients were treated.
• The regimen included paritaprevir/ritonavir, ombitasvir, and dasabuvir, with or without ribavirin.
• Patients included treatment-naive and treatment-experienced individuals, predominantly infected with genotype 1b.

Main Results:

• A 100% sustained virological response 12 weeks after therapy termination (SVR12) was achieved.
• This high efficacy was observed across treatment-naive and treatment-experienced groups.
• No virological treatment failures were reported in the analyzed cohort.

Conclusions:

• The combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir is highly effective for chronic hepatitis C.
• This interferon-free regimen offers a promising treatment option in the Czech Republic.
• Real-world data confirm the excellent outcomes of this direct-acting antiviral therapy.